ERBB2 and breast carcinoma: miR-223 has been readily discussed in the context of various cancers, e.g., affecting cellular proliferation, migration and epithelial to mesenchymal transition via the Yap/Hippo signaling in breast cancer cells [71], histamine N-methyltransferase/HER2 mediated chemoresistance [72] and apoptosis regulation via the PI3K/AKT pathway [73], amongst others [53].